Utilization of Madin-Darby Canine Kidney MDCK Cells for Manufacture of Inactivated Influenza Vaccines: Introduction .


123 views
Uploaded on:
Category: Music / Dance
Description
Utilization of Madin-Darby Canine Kidney (MDCK) Cells for Assembling of Inactivated Flu Antibodies: Presentation. Philip R. Krause, M.D. Layout. Definitions and brief prologue to the issues Late history of contemplating neoplastic cell substrates
Transcripts
Slide 1

Utilization of Madin-Darby Canine Kidney (MDCK) Cells for Manufacture of Inactivated Influenza Vaccines: Introduction Philip R. Krause, M.D.

Slide 2

Outline Definitions and brief prologue to the issues Recent history of pondering neoplastic cell substrates Summary of logical concerns with respect to utilization of neoplastic cell substrates Brief portrayal of the arrangement for now\'s meeting

Slide 3

Definitions Neoplastic cells (ceaseless cell lines) Cells that are deified and can advance along the pathway to tumor development Tumorigenic cells Neoplastic cells that shape tumors when infused into powerless creatures Highly tumorigenic cells-frame tumors at low cell measurements, or shape metastatic tumors Weakly tumorigenic cells-frame tumors just at higher cell dosages

Slide 4

Cell substrates utilized for immunization generation Primary cells & Tissues (1954) Calf lymph for smallpox antibodies Monkey kidney cells for polio antibodies Embryonated hens\' eggs for flu, yellow fever immunizations Chicken incipient organism cell culture for measles, mumps antibodies Mouse mind for inactivated JEV antibody Human diploid cells (presented in 1960s) MRC-5, WI-38 for rubella, varicella antibodies CHO cells for profoundly refined, subunit investigational immunizations (1980s) Vero cells at non-tumorigenic entries for exceedingly cleansed, inactivated immunization (IPV) (1980s) Vero cells at non-tumorigenic sections for live-lessened immunizations (late 1990s) In vitro changed human cells (e.g., 293, PER.C6) for replication-imperfect recombinant immunizations (mid 2000s)

Slide 5

History of MDCK cells Multiple, generally free subordinates of the MDCK cell line have been depicted 1958, MDCK built up from sound female cocker spaniel MDCK, ATCC 1963 MDCK-USD 1961 MDCK-NIH From Gaush, PSEBM, 1996 122:931

Slide 6

Why are MDCK Cells being considered for use in produce of inactivated flu immunizations? Infection development advantage More fast scale-up Ability to bank & altogether portray cells Adaptation to without serum development Manufacturers will give more detail

Slide 7

Issues with MDCK Cell Substrates Original line of MDCK cells was non tumorigenic Some MDCK subsidiaries have been observed to be profoundly tumorigenic Highly tumorigenic cell substrates have never been utilized to make viral immunizations Highly tumorigenic cell substrates posture noteworthy administrative difficulties

Slide 8

Introducing tumorigenic cell lines for antibody improvement Expands the collection of neoplastic cells that can be utilized as a part of advancement of new immunizations, including: hereditarily designed viral vectored antibodies HIV antibodies Influenza antibodies yearly pandemic

Slide 9

Why are there worries about tumorigenic cells? Potential for expanded danger of extrinsic operator tainting Potential for expanded hazard related with remaining DNA Potential for expanded hazard related with infection/cell collaborations Potential for other expanded dangers? Impression of expanded hazard

Slide 10

The following slides will depict the previous 10 or so years of CBER pondering presentation of neoplastic cell substrates

Slide 11

Neoplastic cells being used in 1995 for creation of biologicals Namalwa cells for interferon Rodent cells for monoclonal antibodies (hybridomas), restorative proteins (CHO and BHK), including CHO cells for investigational protein subunit immunizations These phones are tumorigenic Non-irresistible retroviruses are available High measures of viral disposal/inactivation (leeway) are required no less than 6 logs freedom in overabundance of known retrovirus weight; can by and large just be shown with various "orthogonal strides" Vero cells, at non-tumorigenic entries, utilized for generation of inactivated poliovirus immunizations Stringent constraints on DNA content Used just for inactivated antibodies

Slide 12

VRBPAC discourses in regards to neoplastic cell substrates Based on the commence that full open examination of move to utilization of neoplastic cell substrates is imperative 1998: Initial exchange with panel 1999: International cell substrate meeting & answer to VRBPAC 2000: Discussion of the utilization of Vero cells 2001: Discussion of 293 and PER.C6 cells

Slide 13

11/19/1998 VRBPAC: Initial Discussion with Committee prescribed: Development of a report portraying a proposed way to deal with tending to utilization of neoplastic cells in antibody fabricate A workshop to acquire open talk of this archive and extra logical contribution on these issues Continued discourse with the consultative council Research to give logical establishment to basic leadership in regards to utilization of neoplastic cells in antibody make

Slide 14

September 1999: International Meeting: Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development Sponsored by: CBER, IABs, NIAID, NVPO, WHO Summarized at 9/14/99 VRBPAC Goals: Identify concerns & issues Identify ways to deal with decide levels of hazard related with those issues Discussion of CBER record arranged in light of 11/98 VRBPAC Presentation of "Characterized Risks Approach" as a calculated structure for considering the issues

Slide 15

Defined dangers approach Represents an endeavor to build up, where conceivable, a quantitative applied system for evaluating upper limits on potential dangers Identifying the conceivable hazard occasion Estimating or deciding the recurrence with which the hazard occasion may happen or has been seen to happen, either in nature or under test conditions Estimating the conceivable recurrence of the hazard occasion per dosage of antibody Developing and deciding the affectability of at least one examines that can be utilized to recognize the hazard occasion Developing and approving at least one procedures that can be utilized to set up an item particular security figure

Slide 16

1999 meeting: Scientific conclusions Multi-calculate nature of carcinogenesis recommends okay of oncogenicity from cell segments other than oncogenic infections Unrecognized unusual operators might be the real worry with neoplastic cell substrates Primary cells display more serious dangers for extrinsic specialists than neoplastic cells Risks from leftover DNA were seen to be low, in spite of the fact that there is a requirement for more logical information to confirm this observation Virus/cell associations : Risk must be viewed as in view of particular infection/cell substrate blends, and any specific weights in the phone culture framework Concern was raised that neoplastic cells could contain strange PrP qualities, of vague noteworthiness Designing cell substrates utilizing characterized instruments of change ought to be considered

Slide 17

VRBPAC 2000: Issues/Topics in regards to Vero cell use for immunization make Vero cells Non-tumorigenic, yet have ability to end up tumorigenic upon rehashed entry Mechanism of change is obscure Substantial experience exists utilizing Vero cells in research and diagnostics High level of testing identified no proof for the nearness of extrinsic specialists

Slide 18

VRBPAC 2000: Conclusions/Recommendations on Vero cell use for antibody make Importance of guaranteeing expulsion of in place cells from immunization More worry about parenteral than mucosal antibodies delivered in Vero cells Significant concern communicated about utilization of Vero cells at tumorigenic section levels Some individuals communicated worry about utilizing cells with the possibility to end up tumorigenic Limit DNA to 10 ng for antibodies delivered in Vero cells at non-tumorigenic sections

Slide 19

VRBPAC 2001: Issues/Topics on in vitro-changed neoplastic cells to create replication-deficient antibodies 293, PER.C6 cells for quality treatment items, investigational live adenovirus vectored antibodies These phones permit replication of imperfect adenovirus vectors (PER.C6 intended to limit RCA development) Defined component of change (Ad5 E1) These phones are feebly tumorigenic Extensive testing distinguished no confirmation of the nearness of extrinsic operators

Slide 20

VRBPAC 2000: PER.C6 and 293 cells for antibody make Discussed estimation of these phones for assembling vectored viral antibodies Discussed part of known instrument of change including some doubt this gave an unmistakable wellbeing edge Discussed significance of limiting strides (i.e. start occasions) toward oncogenesis in antibody beneficiaries (regardless of the possibility that oncogenic result is not specifically corresponded with utilization of neoplastic cells, guarantee that immunization beneficiaries are not "prepared")

Slide 21

VRBPAC 2001: PER.C6 and 293 cells for immunization produce (proceeded with) Discussed adenovirus E1 quality: low probability of take-up in countless inclusion in apoptosis unrealisticness of achieving tumor cell edge measurement vital for clinical effect Discussed whether level of tumorigenicity was vital changing feelings Discussed way to deal with TSE issues in neoplastic or retinal cells Conclusion that these phones could be utilized for make of replication inadequate adenovirus immunizations, with fitting confinement on leftover DNA.

Slide 22

The following slides will compress the worries that might be related with presenting new neoplastic cell substrates

Slide 23

Concerns in regards to utilization of neoplastic or tumorigenic cells-1 Tumorigenic cells may frame tumors if exchanged to a beneficiary Has been accounted for with human cells Unlikely if cells are non-human, because of immunological xenograft dismissal instruments Addressed by guaranteeing ( by means of approved techniques) nonappearance of in place cells in conclusive item

Slide 24

Concerns in regards to utilization of neoplastic or tumorigenic cells-2 Special contemplations in regards to unusual operators Adventitious operators that may have actuated the first neoplastic or tumorigenic phenotype might be available in the cells Some infections are known cancer-causing agents in creatures and people Neoplastic or tumorigenic cells may have extended ability to bolster viral replication, an

Recommended
View more...